Press release
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Future of Treatment, analyses DelveInsight
Liver Cancer Clinical Trial
Stay informed with cutting-edge developments! Access DelveInsight's detailed Liver Cancer Pipeline Report to uncover emerging therapies, leading developers, and the future direction of liver cancer treatment @ Liver Cancer Pipeline Outlook Report - https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Liver Cancer Pipeline Report
• August 2025: Hoffmann-La Roche initiated a Phase Ib/II clinical trial in patients with advanced liver cancers. The adaptive study design allows for the addition of new treatment arms, closure of arms with limited efficacy or safety concerns, adjustments to patient populations, and inclusion of new cohorts with other advanced primary liver cancer subtypes.
• July 2025: Bristol-Myers Squibb launched a clinical study assessing the safety and efficacy of relatlimab combined with nivolumab in patients with advanced liver cancer who are immunotherapy-naïve but previously treated with tyrosine kinase inhibitors.
• DelveInsight's analysis highlights a highly competitive and active liver cancer pipeline, with over 70 organizations developing more than 75 investigational therapies.
• Key players in the liver cancer landscape include Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co., Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb, and others.
• Notable liver cancer therapies in development include Atezolizumab, Bevacizumab, Tiragolumab, OH2 Injection, MTL-CEBPA, Sorafenib 200 mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, among others.
Explore how the liver cancer treatment landscape is transforming. Gain deeper insights into novel assets and clinical progress through DelveInsight's comprehensive pipeline evaluation
@ Liver Cancer Clinical Trials and Studies - https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Liver Cancer Emerging Drugs Profile
• Namodenoson: Can-Fite BioPharma
Namodenoson is an orally administered small-molecule agent, also known as Cl-IB-MECA, that selectively targets the A3 adenosine receptor (A3AR). Its mechanism involves modulation of the NF-κB and Wnt signaling pathways, triggering tumor cell apoptosis. Additionally, the drug exerts protective effects by suppressing NF-κB-mediated signaling, thereby preventing excessive apoptosis.
Namodenoson has demonstrated strong anti-tumor activity - particularly in hepatocellular carcinoma - along with anti-inflammatory effects in preclinical liver inflammation models. Favorable safety outcomes have been observed in preclinical studies as well as Phase I and II clinical trials. The therapy is currently undergoing Phase III clinical development for advanced liver cancer.
• YIV-906: Yiviva
YIV-906 (also known as PHY906 or KD018) is a proprietary, cGMP-grade botanical formulation derived from four medicinal herbs rooted in traditional Chinese medicine. Designed as a platform oncology therapy, YIV-906 is intended for use alongside chemotherapy, immunotherapy, and radiation across multiple cancer indications. The compound has been shown to enhance immune activity within the tumor microenvironment, protect gastrointestinal tissues by suppressing inflammatory pathways (including IL-6, NF-κB, COX-2, and iNOS), and stimulate intestinal repair via Wnt pathway activation. Preclinical data suggest synergistic anti-tumor effects when combined with sorafenib in hepatocellular carcinoma, with encouraging early clinical signals in liver, pancreatic, colorectal, and rectal cancers. YIV-906 is currently in Phase II clinical trials for liver cancer.
• TTI-101: Tvardi Therapeutics
TTI-101 is an orally available small-molecule inhibitor targeting STAT3, a transcription factor implicated in cancer progression, inflammation, and fibrosis. Preclinical studies have demonstrated favorable pharmacokinetics, potent inhibition of STAT3 phosphorylation, and significant tumor growth suppression in multiple cancer models. The therapy has advanced into Phase II clinical evaluation.
• STP707: Sirnaomics
STP707 is an RNA interference-based therapeutic candidate in early-stage development for solid tumors, including liver cancer. Administered intravenously, it simultaneously inhibits TGF-β1 and COX-2, utilizing Sirnaomics' proprietary PNP delivery platform. The drug is currently being assessed in a Phase I clinical trial.
• BST02: BioSyngen
BST02 is an adoptive cell therapy derived from the expansion of a patient's own tumor-infiltrating lymphocytes (TILs). Designed to address all forms of liver cancer, BST02 offers advantages over conventional TIL therapies, including cryopreservation for logistical flexibility and reduced dependence on high-dose interleukin-2. The therapy is currently undergoing Phase I clinical testing.
Insights Offered by the Liver Cancer Pipeline Report
• Comprehensive profiling of companies developing liver cancer therapies, including the total number of assets per organization
• Classification of therapeutic candidates across early, mid, and late stages of development
• Coverage of both active and inactive (discontinued or dormant) pipeline programs
• Segmentation of drugs by development stage, administration route, molecular class, therapeutic modality, target, and mechanism of action
• In-depth evaluation of strategic collaborations, licensing deals, and funding activities shaping future market growth
Gain a strategic view of the most recent innovations shaping the liver cancer pipeline. Explore DelveInsight's expert-led analysis today @ Liver Cancer Unmet Needs - https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Liver Cancer Companies
Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co., Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb, and others.
Therapeutic Assessment by Route of Administration (ROA)
Pipeline therapies are categorized based on administration routes, including:
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Therapeutic Assessment by Molecule Type
Liver cancer pipeline assets are segmented into:
• Oligonucleotides
• Peptides
• Small molecules
Download DelveInsight's latest report to uncover strategic insights into upcoming liver cancer therapies and key industry developments @ Liver Cancer Market Drivers, Barriers, and Future Outlook - https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Liver Cancer Pipeline Report
• Geographical Coverage: Global
• Companies Covered: Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co., Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb, and others
• Therapies Covered: Atezolizumab, Bevacizumab, Tiragolumab, OH2 Injection, MTL-CEBPA, Sorafenib 200 mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others
• Therapeutic Modalities: Monotherapy, combination therapy, and mono/combination approaches
• Development Stages: Discovery, preclinical, Phase I, Phase II, and Phase III
Which companies are shaping the future of liver cancer drug development? Discover the leaders and breakthrough therapies in DelveInsight's exclusive Liver Cancer Pipeline Report - access it now @ Liver Cancer Emerging Drugs and Major Companies - https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Future of Treatment, analyses DelveInsight here
News-ID: 4345131 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
